FibroBiologics raises $0.5 million from CSO Hamid Khoja in private placement
The Houston biotech sold stock and warrants to its Chief Scientific Officer at $1.675 per unit, expecting to close the deal the same day.
FibroBiologics, Inc. entered into a securities purchase agreement on September 15, 2026 with Hamid Khoja, Ph.D., the company's Chief Scientific Officer, for a private placement of stock and warrants. The agreement covers the issuance and sale of 298,508 shares of common stock along with warrants to purchase up to another 298,508 shares.1
The offering price is set at $1.675 per share and accompanying warrant, matching the Nasdaq Capital Market's consolidated closing bid price of $1.55 per share on September 14, 2026 plus $0.125 per warrant.1 Gross proceeds to the company are expected to total approximately $0.5 million before offering expenses.1 FibroBiologics said it plans to use the net proceeds for general corporate purposes and working capital.1 The offering was expected to close on September 15, 2026, subject to customary closing conditions.1
On warrant terms, the warrants become exercisable any time after issuance at an exercise price of $1.55 per share and expire five years after issuance, with cashless exercise provisions.1 The warrants also carry standard anti-dilution adjustments for events such as stock splits, stock dividends, rights offerings and pro rata distributions.1
The maximum number of shares issuable through warrant exercise is 298,508, subject to those anti-dilution adjustments.1
The transaction was structured as an unregistered sale. The company said the offer and sale rely on the exemption under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, and the securities have not been registered under the Securities Act or applicable state securities laws.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.